Monday, November 20, 2017 1:50:55 AM
It makes sense that they aren’t spending thousands upon thousands of $$ in perpetuity on “development”. At some point the product is “developed” and you would expect those costs to lessen significantly.
The argument is like asking why a company up for FDA approval on a drug is no longer sinking millions of dollars into R&D on that drug. The answer is that that phase of the Model is over and that is not where the money needs to currently go.
Everything pretty much makes sense when you look at all the financials - we are talking a “startup” here, not a seasoned company...
I do note that your link shows a jump in accounts receivable in the 3 months prior - nice to see.
Following the charts is like driving a car forward while looking in the rear view mirror.
Axis Technologies Group and Carbonis Forge Ahead with New Digital Carbon Credit Technology • AXTG • Apr 24, 2024 3:00 AM
North Bay Resources Announces Successful Equipment Test at Bishop Gold Mill, Inyo County, California • NBRI • Apr 23, 2024 9:41 AM
Epazz, Inc.: CryObo, Inc. solar Bitcoin operations will issue tokens • EPAZ • Apr 23, 2024 9:20 AM
Avant Technologies Launches Advanced AI Supercomputing Network and Expansive Data Solutions • AVAI • Apr 23, 2024 8:00 AM
BestGrowthStocks.com Issues Comprehensive Analysis of Triller Merger with AGBA Group Holding Limited • AGBA • Apr 22, 2024 1:00 PM
Cannabix Technologies to Present Marijuana Breathalyzer Technology at International Association for Chemical Testing (IACT) Conference in California • BLO • Apr 22, 2024 8:49 AM